These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 29437613)
21. Parallel Evolution of Tobramycin Resistance across Species and Environments. Scribner MR; Santos-Lopez A; Marshall CW; Deitrick C; Cooper VS mBio; 2020 May; 11(3):. PubMed ID: 32457248 [TBL] [Abstract][Full Text] [Related]
22. Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene. Prickett MH; Hauser AR; McColley SA; Cullina J; Potter E; Powers C; Jain M Thorax; 2017 Jan; 72(1):40-47. PubMed ID: 27325751 [TBL] [Abstract][Full Text] [Related]
23. Insights into the evolution of the mutational resistome of Pseudomonas aeruginosa in cystic fibrosis. López-Causapé C; Oliver A Future Microbiol; 2017 Dec; 12():1445-1448. PubMed ID: 29068237 [No Abstract] [Full Text] [Related]
24. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria. Strateva T; Petrova G; Mitov I J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744 [TBL] [Abstract][Full Text] [Related]
25. Within-host whole genome analysis of an antibiotic resistant Pseudomonas aeruginosa strain sub-type in cystic fibrosis. Sherrard LJ; Tai AS; Wee BA; Ramsay KA; Kidd TJ; Ben Zakour NL; Whiley DM; Beatson SA; Bell SC PLoS One; 2017; 12(3):e0172179. PubMed ID: 28273168 [TBL] [Abstract][Full Text] [Related]
26. PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients. Moskowitz SM; Brannon MK; Dasgupta N; Pier M; Sgambati N; Miller AK; Selgrade SE; Miller SI; Denton M; Conway SP; Johansen HK; Høiby N Antimicrob Agents Chemother; 2012 Feb; 56(2):1019-30. PubMed ID: 22106224 [TBL] [Abstract][Full Text] [Related]
28. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Sobel ML; McKay GA; Poole K Antimicrob Agents Chemother; 2003 Oct; 47(10):3202-7. PubMed ID: 14506031 [TBL] [Abstract][Full Text] [Related]
29. Mechanism of amikacin resistance in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Hurley JC; Miller GH; Smith AL Diagn Microbiol Infect Dis; 1995 Aug; 22(4):331-6. PubMed ID: 8582138 [TBL] [Abstract][Full Text] [Related]
30. Transcriptional and Mutational Profiling of an Aminoglycoside-Resistant Pseudomonas aeruginosa Small-Colony Variant. Schniederjans M; Koska M; Häussler S Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874369 [No Abstract] [Full Text] [Related]
31. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study. Millar BC; Rendall JC; Downey DG; Moore JE J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786 [TBL] [Abstract][Full Text] [Related]
32. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters. Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275 [TBL] [Abstract][Full Text] [Related]
33. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way? Banerjee D; Stableforth D Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122 [TBL] [Abstract][Full Text] [Related]
34. Multiple mutations lead to MexXY-OprM-dependent aminoglycoside resistance in clinical strains of Pseudomonas aeruginosa. Guénard S; Muller C; Monlezun L; Benas P; Broutin I; Jeannot K; Plésiat P Antimicrob Agents Chemother; 2014; 58(1):221-8. PubMed ID: 24145539 [TBL] [Abstract][Full Text] [Related]
35. Involvement of Acquired Tobramycin Resistance in the Shift to the Viable but Non-Culturable State in Mangiaterra G; Cedraro N; Vaiasicca S; Citterio B; Frangipani E; Biavasco F; Vignaroli C Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511375 [TBL] [Abstract][Full Text] [Related]
36. ISPa46, a novel insertion sequence in the oprD porin gene of an imipenem-resistant Pseudomonas aeruginosa isolate from a cystic fibrosis patient in Marseille, France. Diene SM; L'homme T; Bellulo S; Stremler N; Dubus JC; Mely L; Leroy S; Degand N; Rolain JM Int J Antimicrob Agents; 2013 Sep; 42(3):268-71. PubMed ID: 23880169 [TBL] [Abstract][Full Text] [Related]
37. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Lang BJ; Aaron SD; Ferris W; Hebert PC; MacDonald NE Am J Respir Crit Care Med; 2000 Dec; 162(6):2241-5. PubMed ID: 11112146 [TBL] [Abstract][Full Text] [Related]
38. Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa. Schurek KN; Marr AK; Taylor PK; Wiegand I; Semenec L; Khaira BK; Hancock RE Antimicrob Agents Chemother; 2008 Dec; 52(12):4213-9. PubMed ID: 18824604 [TBL] [Abstract][Full Text] [Related]
39. Recombination is a key driver of genomic and phenotypic diversity in a Pseudomonas aeruginosa population during cystic fibrosis infection. Darch SE; McNally A; Harrison F; Corander J; Barr HL; Paszkiewicz K; Holden S; Fogarty A; Crusz SA; Diggle SP Sci Rep; 2015 Jan; 5():7649. PubMed ID: 25578031 [TBL] [Abstract][Full Text] [Related]